Departmental Research

Alzheimer’s Sponsor PI

36-5250-2016-001 301 Non-Carrier

Janssen Alzheimer Immunotherapy Research and Development. Phase III multicenter randomized, double blind, placebo controlled parallel group. Carriers (302) and non-carriers (301)

Recruitment Closed

Janssen Al, Murman

36-5250-2015-001 302 Carrier

Janssen Alzheimer Immunotherapy Research and Development. Phase III multicenter randomized, double blind, placebo controlled parallel group. Carriers (302) and non-carriers (301)

Recruitment Closed

Janssen Al, Murman

36-5250-2021-001 Elan 351

Janssen A1 AAB-001 (bepineuzamab) open-label, together extension study in patients with mild to moderate Alzheimer's disease

Recruitment open

Janssen Al. Murman

36-5250-2022-001 Pharmacoeconomic

Investigator Initial Janssen Al " Modeling the impact of dependency on pharmacoeconmic outcomes in Alzheimer's disease (Elan2)

Recruitment open

Janssen AI. Murman

Prodromal

A Phase 3, Randomized, Double Blind, Placebo Controlled, Multicenter, Efficacy, and Safety Study of Bapineuzumab Administered Subcutaneously at

NEW Pending

Janssen AI Murman
Parkinson's Disease    

STEADY PD3

Safety, Tolerability, and Efficacy Assessment of Dynacirc CR for Parkinson’s Disease

NEW Pending

NIH sub-award with Univ Rochester Bertoni

36-5250-2019-001 S187.3.004

Open-Label 12 Month Safety and Efficacy Study of Levodopa-Caridopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications

Recruitment closed

Solvay Bertoni

36-5250-2020-001 ADAGIO

An Open-label, MultiCenter, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study

Recruitment closed

Teva Bertoni
Merck Serono, SA Safinamide Trial Merck Serono Bertoni
Open-Label 12 Month Safety and Efficacy Study of Levodopa-Caridopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects Solvay Bertoni
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations Solvay Bertoni

Progeni Family Study

Recruitment open

MJFF Bertoni

36-5250-2024-001 S187.3.002

Recruitment closed

Solvay Bertoni

36-5250-2027-001 S187.3.003

Recruitment closed

Solvay Bertoni

36-5250-2023-001 PostCept

A Longitudinal Observational Follow-up of the PRECEPT Study Cohort

Recruitment closed

NIH/Univ of Rochester Bertoni

DCVPF

Differentiation of Central vs Peripheral Fatigue in Parkinson’s Disease

New Pending

NIH Sub w/Creighton Bertoni

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 5-Arm, Parallel-Group Trial to Assess Rotigotine Transdermal System Dose Response tin Subjects with Advanced -Stage Parkinson's Disease

Recruitment closed

Bertoni
Stroke    

36-5250-2013-001 IRIS

Insulin Resistance Intervention after Stroke

Recruitment closed

NIH sub-award from Yale University Fayad

36-5250-2012-001 RESPECT

The Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment

Recruitment closed

AGA Medical Fayad
Capture 2 Study --05-716 Carotid RX ACCULINK/ACCUNET Post -Approval Trial To Uncover Unanticipated and Rare Events Fayad  

AVF

Augmented Visual Feedback for Learning Movements in Unpredictable Environments: Behavioral and Brain Correlates in Stoke Patients

New Pending

NIH sub-award from UNL Fayad

EVP

The Effect of Visual Perception of Self Motion on Locomotor Adaptation after Stroke

NIH sub-award from UNO Fayad

Stem Cell Protocol # B01-02

Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem in Adults with Ischemic Stroke

New Pending

Athersys Fayad
Multiple Sclerosis    

36-5250-2026-001 Stratify 2

JCV Antibody Program in Patients with Relapsing MS Receiving or Considering Treatment with Tysabri

Recruitment Open

Biogen Zabad

OPERA

Randomized, Double-Blink, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy & Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif) in Patients with Relapsing MS

Recruitment Open

Roche Zabad

ASCEND

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Patients with Secondary Progressive Multiple Sclerosis

Recruitment Open

Biogen Zabad

The Role of Ancanthamoeba Castellani in the Pathophysiology of Multiple Sclerosis

Recruitment Open

UNL Dr Reddy Zabad

NMR

 Developing NMR Metabolomics as a Diagnostic Tool for Multiple Sclerosis & Pancreatic Cancer

Pending

NIH Subaward w/UNL Zabad

BMI

Brain Mechanical Imaging for CNS

Pending

NIH Subaward w/UNL Zabad

PoNS

Randomized Clinical Trial for the PoNS that will be Performed at UNMC

Pending

In design stage Zabad
ALS    

COSMOS

Multicenter ALS Cohort Study of Oxidative Stress & Disease Progression

Pending

NIH/NIEHS & MS Association w/Columbia University Fernandes

36-5250-2029-001 Rasagiline

A Multi-Center Screening Trial of Safety & Efficacy of Rasagiline in Subjects with Amyotrophic Lateral Sclerosis (Rasagiline)

Recruitment Open

UKMC & Western ALS Study Group Fernandes

NEALS

The Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) Reliability Studies: Outcome Measures in Amyotrophic Lateral Sclerosis Research

NEALS Fernandes

;